Efficacy and safety associated with the infusion speed of intravenous immunoglobulin for the treatment of Kawasaki disease: a randomized controlled trial

Efficacy and safety associated with the infusion speed of intravenous immunoglobulin for the treatment of Kawasaki disease: a randomized controlled trial

Abstract Background High-dose intravenous immunoglobulin (IVIG) is the mainstay of treatment for Kawasaki disease (KD). Usually, 2 g/kg of IVIG is administered over 10–24 h, depending on the institution or physician, but the association between infusion speed and effectiveness has not been reported....

Full description

Bibliographic Details
Main Authors: Saori Fukui, Mitsuru Seki, Takaomi Minami, Kazuhiko Kotani, Kensuke Oka, Akiko Yokomizo, Daisuke Matsubara, Tomoyuki Sato, Yasuyuki Nozaki, Mari Saito, Yutaka Kikuchi, Kenji Miyamoto, Yukifumi Monden, Takanori Yamagata
Format: Article
Language:English
Published: BMC 2021-07-01
Series:Pediatric Rheumatology Online Journal
Subjects:
Kawasaki disease
Intravenous immunoglobulin
IVIG
Randomized study
Safety
Effectiveness
Online Access:https://doi.org/10.1186/s12969-021-00601-6

Internet

https://doi.org/10.1186/s12969-021-00601-6

Similar Items